NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

TerminatedPhase 1

Sponsor: Pfizer

Conditions: Advanced Solid Tumors, Metastatic Solid Tumors

Interventions: PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel

Countries: United States

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC
* Progressed after at least 1 line of treatment and no more than 3 lines of treatment
* At least one measurable lesion as defined by RECIST version 1.1
* ECOG Performance Status 0 or 1
* Adequate Bone Marrow Function
* Adequate Renal Function
* Adequate Liver Function
* Resolved acute effects of any prior therapy

Exclusion Criteria:

* Known active uncontrolled or symptomatic CNS metastases.
* Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.
* Active, uncontrolled infection, including COVID-19
* Known or suspected hypersensitivity to PF-06939999
* Inability to consume or absorb study drug

Locations (22)

Scottsdale, Arizona, United States
Scottsdale, Arizona, United States
Los Angeles, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Pasadena, California, United States
Celebration, Florida, United States
Celebration, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
Orlando, Florida, United States
Orlando, Florida, United States
Ann Arbor, Michigan, United States
Brighton, Michigan, United States
Nashville, Tennessee, United States
Nashville, Tennessee, United States
Houston, Texas, United States
San Antonio, Texas, United States
Fairfax, Virginia, United States
Seattle, Washington, United States
Seattle, Washington, United States